Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Eletriptan
Drug ID BADD_D00755
Description Eletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches.
Indications and Usage For the acute treatment of migraine with or without aura in adults.
Marketing Status approved; investigational
ATC Code N02CC06
DrugBank ID DB00216
KEGG ID D07887
MeSH ID C115647
PubChem ID 77993
TTD Drug ID D02DMQ
NDC Product Code Not Available
UNII 22QOO9B8KI
Synonyms eletriptan | (R)-3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole | UK 166,044 | UK-166044 | UK 166044 | UK-166,044 | Relpax | UK-116044-04 | UK-116,044-04 | eletriptan hydrobromide | (R)-3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole monohydrobromide | 3-(1-methyl-2-pyrrolidinylmethyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole hydrobromide
Chemical Information
Molecular Formula C22H26N2O2S
CAS Registry Number 143322-58-1
SMILES CN1CCCC1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Decreased appetite08.01.09.028; 14.03.01.005--
Erectile dysfunction19.08.04.001; 21.03.01.007--
Ill-defined disorder08.01.03.049---
Lacrimal disorder06.08.02.005---
Autoimmune disorder10.04.04.0030.000361%
Respiratory tract infection11.01.08.017; 22.07.07.001---
Increased bronchial secretion22.12.01.002---
Hyperpathia17.02.07.015---
Medication overuse headache08.06.02.015; 17.14.01.0150.002421%-
Lacrimal structural disorder06.06.04.013---
Reversible cerebral vasoconstriction syndrome17.08.02.014; 18.06.01.004; 24.04.06.0260.000542%-
Candida infection11.03.03.021--
Depersonalisation/derealisation disorder19.14.01.004---
Drug use disorder19.07.06.0120.000723%-
Heavy menstrual bleeding21.01.03.005---
Illness08.01.03.0910.001410%-
Status migrainosus17.14.02.007; 24.03.05.0200.000542%-
Therapeutic product effect incomplete08.06.01.0520.005277%-
Vulvovaginal inflammation21.14.02.014---
The 10th Page    First    Pre   10    Total 10 Pages